Calhoun Lesley Ann 4

What Happened
Lesley Ann Calhoun, a director of Tango Therapeutics (TNGX), was granted two awards on June 5, 2026: 4,000 restricted stock units (RSUs) and a 25,000-share derivative award (an option/derivative). Both awards show an acquisition price of $0.00 (i.e., no cash paid). These are grants/compensation rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (filed timely).
• Grants reported: 4,000 shares (RSUs) at $0.00; 25,000 shares (derivative) at $0.00.
• Shares owned after transaction: not specified in this filing.
• Footnote F1 (RSUs): Each RSU converts to one share and vests in full on the earlier of June 5, 2027 or the next annual meeting, subject to continuous service.
• Footnote F2 (derivative): The option vests in 12 substantially equal monthly installments over one year, beginning July 5, 2026, subject to continuous service.
• Filing includes Exhibit 24 (Power of Attorney).

Context
RSU grants convert to actual shares only upon vesting; the 25,000-share item is a derivative option that vests monthly (not an immediate sale or cash exercise). Such director awards are common forms of compensation and do not by themselves indicate buying or selling sentiment. This Form 4 was filed within the required reporting window.